165 related articles for article (PubMed ID: 2880677)
1. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Goren MP; Forastiere AA; Wright RK; Horowitz ME; Dodge RK; Kamen BA; Viar MJ; Pratt CB
Cancer Chemother Pharmacol; 1987; 19(1):57-60. PubMed ID: 2880677
[TBL] [Abstract][Full Text] [Related]
2. Cumulative renal tubular damage associated with cisplatin nephrotoxicity.
Goren MP; Wright RK; Horowitz ME
Cancer Chemother Pharmacol; 1986; 18(1):69-73. PubMed ID: 2875808
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of methotrexate nephrotoxicity after cisplatin therapy.
Goren MP; Wright RK; Horowitz ME; Meyer WH
Cancer; 1986 Dec; 58(12):2617-21. PubMed ID: 2877729
[TBL] [Abstract][Full Text] [Related]
4. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
[TBL] [Abstract][Full Text] [Related]
5. Enzymuria in carboplatin nephrotoxicity.
Damiani E; Cattaneo MT; Sessa C; Zucca E; Cavalli F; Bertolini A; Libretti A; Beretta R
Tumori; 1987 Oct; 73(5):487-91. PubMed ID: 3318051
[TBL] [Abstract][Full Text] [Related]
6. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).
Skillen AW; Buamah PK; Cantwell BM; Cornell C; Hodson AW; Harris AL
Cancer Chemother Pharmacol; 1988; 22(3):228-34. PubMed ID: 3044631
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
Goren MP; Wright RK; Horowitz ME; Pratt CB
Cancer Treat Rep; 1987 Feb; 71(2):127-30. PubMed ID: 2879626
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
9. Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.
Goren MP; Pratt CB; Viar MJ
Cancer Chemother Pharmacol; 1989; 25(1):70-2. PubMed ID: 2574077
[TBL] [Abstract][Full Text] [Related]
10. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study.
Alberts D; Mason N; Surwit E; Weiner S; Hammond N; Deppe G
Cancer Treat Rev; 1985 Sep; 12 Suppl A():83-92. PubMed ID: 3910225
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
[TBL] [Abstract][Full Text] [Related]
13. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Dimery IW; Legha SS
J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin. The better platinum in head and neck cancer?
Volling P; Schröder M; Rauschning W; Achterrath W; Stennert E
Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):695-8. PubMed ID: 2655667
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.
Pendyala L; Madajewicz S; Lele SB; Arbuck SG; Creaven PJ
Cancer Chemother Pharmacol; 1985; 15(3):203-7. PubMed ID: 4053265
[TBL] [Abstract][Full Text] [Related]
16. Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.
de Wit R; Tesselaar M; Kok TC; Seynaeve C; Rodenburg CJ; Verweij J; Helle PA; Stoter G
Eur J Cancer; 1991; 27(11):1383-5. PubMed ID: 1835851
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
McGuire WP; Arseneau J; Blessing JA; DiSaia PJ; Hatch KD; Given FT; Teng NN; Creasman WT
J Clin Oncol; 1989 Oct; 7(10):1462-8. PubMed ID: 2674333
[TBL] [Abstract][Full Text] [Related]
18. Phase I and II agents in cancer therapy: two cisplatin analogues and high-dose cisplatin in hypertonic saline or with thiosulfate protection.
Fuks JZ; Wadler S; Wiernik PH
J Clin Pharmacol; 1987; 27(5):357-65. PubMed ID: 3320104
[TBL] [Abstract][Full Text] [Related]
19. Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin.
Metz-Kurschel U; Kurschel E; Niederle N; Aulbert E
J Cancer Res Clin Oncol; 1990; 116(2):203-6. PubMed ID: 2182639
[TBL] [Abstract][Full Text] [Related]
20. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA
J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]